Literature DB >> 17669608

Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability.

K Morand1, A C Bartoletti, A Bochot, G Barratt, M L Brandely, F Chast.   

Abstract

Local fungal infections with Candida, Fusarium, Curvularia and Aspergillus can lead to serious ulceration of the cornea and must be treated rapidly. The current treatment consists of 0.15% (w/v) amphotericin B eye drops prepared from Fungizone, containing deoxycholate, irritant for the cornea, which reduces patient compliance. Eye drops based on liposomal amphotericin B (AmBisome would be a convenient alternative; however, according to the manufacturer's instructions, AmBisome can only be kept refrigerated for 1 week after reconstitution. A longer shelf-life at ambient temperature would be preferable for a preparation made in a hospital pharmacy and delivered to patients. Thus, the possibility of storing an ophthalmic preparation of 0.5% (w/v) liposomal amphotericin B after reconstitution was investigated. After 6 months at room temperature or at +2-8 degrees C, the hydrodynamic diameter measured by quasi-elastic light scattering remained constant at 108 +/- 30 nm with a polydispersity index lower than 0.15. Amphotericin B content, checked by a validated HPLC method, was maintained between 94 and 107%. Amphotericin B and soy phosphatidylcholine proportions remained constant, indicating that the liposomes remained intact and retained the drug. These results show the feasibility of an ophthalmic preparation based on liposomal amphotericin B developed in hospital pharmacies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17669608     DOI: 10.1016/j.ijpharm.2007.04.028

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  Long-acting liposomal corneal anesthetics.

Authors:  Changyou Zhan; Claudia M Santamaria; Weiping Wang; J Brian McAlvin; Daniel S Kohane
Journal:  Biomaterials       Date:  2018-08-09       Impact factor: 12.479

2.  Antifungal activity of a liposomal itraconazole formulation in experimental Aspergillus flavus keratitis with endophthalmitis.

Authors:  André Ferraz Goiana Leal; Melyna Chaves Leite; Caroline Sanuzi Quirino Medeiros; Isabella Macário Ferro Cavalcanti; Almir Gonçalves Wanderley; Nereide Stela Santos Magalhães; Rejane Pereira Neves
Journal:  Mycopathologia       Date:  2014-11-28       Impact factor: 2.574

3.  Evaluation of Liposomal and Conventional Amphotericin B in Experimental Fungal Keratitis Rabbit Model.

Authors:  Anup Kumar Ghosh; Shivaprakash Mandya Rudramurthy; Amit Gupta; Hansraj Choudhary; Shreya Singh; Anchal Thakur; Manu Jatana
Journal:  Transl Vis Sci Technol       Date:  2019-06-06       Impact factor: 3.283

Review 4.  Conventional Antifungals for Invasive Infections Delivered by Unconventional Methods; Aerosols, Irrigants, Directed Injections and Impregnated Cement.

Authors:  Richard H Drew; John R Perfect
Journal:  J Fungi (Basel)       Date:  2022-02-21

5.  Development and Optimization of Hyaluronic Acid-Poloxamer In-Situ Gel Loaded with Voriconazole Cubosomes for Enhancement of Activity against Ocular Fungal Infection.

Authors:  Nabil A Alhakamy; Khaled M Hosny; Waleed Y Rizg; Bayan A Eshmawi; Moutaz Y Badr; Awaji Y Safhi; Samar S A Murshid
Journal:  Gels       Date:  2022-04-14

6.  Self-aggregated nanoparticles based on amphiphilic poly(lactic acid)-grafted-chitosan copolymer for ocular delivery of amphotericin B.

Authors:  Wenjun Zhou; Yuanyuan Wang; Jiuying Jian; Shengfang Song
Journal:  Int J Nanomedicine       Date:  2013-09-27

7.  Ocular Dorzolamide Nanoliposomes for Prolonged IOP Reduction: in-vitroand in-vivo Evaluation in Rabbits.

Authors:  Maryam Kouchak; Reza Bahmandar; Neda Bavarsad; Fereydoun Farrahi
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

8.  Rapidly dissolving microneedle patch of amphotericin B for intracorneal fungal infections.

Authors:  Alyaa A Albadr; Ismaiel A Tekko; Lalitkumar K Vora; Ahlam A Ali; Garry Laverty; Ryan F Donnelly; Raghu Raj Singh Thakur
Journal:  Drug Deliv Transl Res       Date:  2021-07-23       Impact factor: 4.617

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.